From: Human immunodeficiency virus in a cohort of systemic lupus erythematosus patients
Patients features | All patients (n = 602) | SLE patients without HIV (n = 591) | SLE patients with HIV (n = 11) | P valuea |
---|---|---|---|---|
Females | 92% (602) | 91.9% (591) | 100% (11) | 1.000 |
European derived | 75.2% (584) | 75.4% (573) | 63.6% (11) | 0.479 |
Smokingb | 38.3% (582) | 37.6% (215) | 80% (11) | 0.009 |
Obesity | 25.3% (502) | 25.9% (127) | 0% (11) | 0.074 |
Age (years) | 48.2±14.9(597) | 48.3±14.9 (586) | 43.1±12.7 (11) | 0.245 |
SLE age at diagnosis (years) | 33.5±14.2 (591) | 33.6±14.2 (580) | 29.9±13.9 (11) | 0.390 |
Malar rash | 55.3% (597) | 56% (586) | 18.2% (11) | 0.015 |
Photosensitivity | 72.1% (598) | 72.4% (587) | 54.5% (11) | 0.191 |
Oral ulcers | 35.6% (598) | 35.6% (587) | 36.4% (11) | 1.000 |
Arthritis | 72.4% (597) | 74.4% (586) | 63.6% (11) | 0.486 |
Serositis | 25.2% (595) | 25% (585) | 36.4% (11) | 0.482 |
Nephritis | 40.9% (596) | 40.5% (585) | 63.6% (11) | 0.134 |
Neurologic disorders | 11.4% (596) | 10.9% (585) | 36.4% (11) | 0.028 |
Psychosis | 6.5% (597) | 6.3% (586) | 18.2% (11) | 0.158 |
Seizures | 6% (597) | 6% (586) | 9.1% (11) | 0.498 |
Hematologic disorders | 75.8% (598) | 75.8% (587) | 72.7% (11) | 0.773 |
Hemolytic anemia | 29.1% (598) | 28,6% (587) | 54,5% (11) | 0.089 |
Leukopenia/Lymphopenia | 55.9% (598) | 56% (587) | 45.5% (11) | 0.549 |
Thrombocytopenia | 21.4% (598) | 21.5% (587) | 18.2% (11) | 1.000 |
Anti-dsDNA | 46% (567) | 46% (556) | 45.5% (11) | 1.000 |
Anti-Sm | 20.8% (549) | 21% (538) | 9.1% (11) | 0.474 |
Anticardiolipin | 27.3% (550) | 27.6% (539) | 9.1% (11) | 0.304 |
Lupus Anticoagulant | 10% (548) | 10.1% (537) | 9.1% (11) | 1.000 |
Anti-Ro | 39.9% (516) | 39.4% (505) | 63.6% (11) | 0.125 |
Anti-La | 13.4% (515) | 13.1% (504) | 27.3% (11) | 0.172 |
Anti-RNP | 31.1% (515) | 31.2% (504) | 27.3% (11) | 1.000 |
SLEDAI (median)c | 1 (415) | 1 (407) | 0 (11) | 0.550 |
SLICC damage index (median)c | 1 (559) | 1 (551) | 2 (11) | 0.047 |